Owing to its emerging role in neuropsychiatric disorders and to the phenotypic overlap between autism and PMS, SHANK3 has become a target for mutation screening in patients with autistic spectrum disorders (ASD) and several studies [19]–[21] have discovered de novo mutations in such patients. This evidence concerns the gene SHANK3 and autism spectrum disorder.